ProtoKinetix has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP-treated cells showed a dramatic increase in survivability versus untreated cells over a 4-week period, the company is now expanding the study. The new study will include two animal models over a longer period of time to test whether the AAGP-treated cells continue to develop into retinal cells to potentially restore vision in humans.
The study conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
The studies to date demonstrated that in vitro pre-treatment of PPCs with 4 mg/mL PKX-001 resulted in a substantial increase of cell survival following their transplantation into the subretinal area of immunocompromised rabbits with retinal degeneration. PPCs treated with PKX-001 maintained their ability to express key proteins associated with photoreceptor functions, according to ProtoKinetix.
Based on the results thus far, ProtoKinetix now has patents pending in the United States of America, Canada, and Europe.
ProtoKinetix will now extend its previous studies into further in vivo functional studies. To date, the company has histological data ex vivo and in vivo that PKX-001 improves PPC survival and that these cells mature to express proteins of mature photoreceptors.
The global ophthalmic therapeutics/drug market is expected to reach $35.7 billion by 2025, according to a new report by Grand View Research.